<DOC>
	<DOCNO>NCT00216515</DOCNO>
	<brief_summary>The purpose study assess efficacy galantamine attention patient Alzheimer 's Disease , improvement attention Alzheimer 's Disease patient affect activity daily live , global benefit galantamine .</brief_summary>
	<brief_title>The Efficacy Galantamine Attention Frontal Function Patients With Dementia Alzheimer Type</brief_title>
	<detailed_description>Recent study suggest attention deficit occur early stage Alzheimer 's disease affect patient ' activity daily live . In word , patient without language visuospatial dysfunction severe impairment activity daily live , might result attention deficit . Another recent clinical study show galantamine effective attention vigilance Alzheimer 's disease patient donepezil . The study hypothesis galantamine improve attention frontal executive function Alzheimer 's disease patient well-tolerated . 8 mg/day first 4 week , 16 mg next 8 week</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Male female patient age 50 year old Alzheimer 's disease accord criterion DSMIV15 , NINCDSADRDA16 Measuring standard MMSEK 10 26 Patients literate Dementia patient nurse family Patients submit write consent enter clinical trial ( guardian consent also effective ) If patient take AChEI ( Tacrine , Donepezil , Rivastigmine ) treat dementia , patient enter clinical trial long he/she take drug within 15 day begin clinical trial Neurodegenerative disease ( e.g . Parkinson 's disease , Pick 's disease , Huntington 's disease , Down syndrome ) Dementia relate head trauma dementia relate brain damage due cerebral hypoxia ( hypoxic brain damage cardiopulmonary resuscitation , hypoxic brain damage surgery , hypoxic brain damage due addiction , hypoxic brain damage due shock ) brain tumor , nerve syphilis , meningitis , encephalitis , brain tumor amentia epilepsy major psychiatric patient major depression schizophrenia treatmentresistant gastric peptic ulcer patient clinically serious hepatic , renal , lung , endocrinal metabolic disease ( thyroid , parathyroid , pituitary , renal failure , diabetes mellitus ) patient complain severe difficulty urination patient undergone heart surgery within 6 month patient experience myocardial infarction , patient untreated congestive heart failure , patient severe disorder mitral valve aortic valve patient take investigational drug within past 1 month begin day clinical trial patient uncontrolled diabetes mellitus ( patient take medication consults doctor regular basis , he/she participate clinical trial ) patient experienced hypersensitivity allergy cholinesterase inhibitor patient give consent clinical trial , patient judge inappropriate participate clinical trial investigator</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>galantamine</keyword>
	<keyword>attention</keyword>
	<keyword>executive function</keyword>
</DOC>